COHERUS BIOSCIENCES WKN: A12ETZ ISIN: US19249H1032 Kürzel: 8C5 Forum: Aktien Thema: Hauptdiskussion

Schau Mal was AI dazu sagt, The roughly $60 million decrease in cash at Coherus BioSciences from Q2 to Q3 2024 was largely due to operational costs and investments focused on growing its oncology portfolio. Key cash outflows included substantial research and development (R&D) expenditures to advance clinical trials for immuno-oncology treatments and pipeline assets, as well as marketing costs associated with launching its cancer treatments, such as LOQTORZI (a PD-1 inhibitor for nasopharyngeal carcinoma)​​​​. Additionally, although Coherus has seen rising revenue from products like UDENYCA, which experienced increased sales in 2024, these gains were offset by ongoing restructuring and expansion-related expenses in both R&D and general administrative areas​​. This strategic shift toward a more focused oncology business has led to higher expenditures as Coherus works on expanding its commercial footprint in cancer therapies.

Coherus BioSciences reported a cash, cash equivalents, and marketable securities balance of $97.7 million at the end of Q3 2024, a decrease from $159.2 million at the end of Q2 2024​​​​.